ArticleJournal of clinical gastroenterology2010
Complementary and alternative medicine use in chronic liver disease patients.
Article in Journal of clinical gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 83 citations in OpenAlex.
- Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial.Pharmaceutics · 2025Article
- Article
- Use of complementary and alternative medicine in patients with chronic liver diseases in Germany- a multicentric observational study.BMC complementary medicine and therapies · 2024Observational
- Complementary and alternative medicines and liver disease.Hepatology communications · 2024Review
- Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.BMC complementary medicine and therapies · 2020Article
- Herbal medicine use among patients with viral and non-viral Hepatitis in Uganda: prevalence, patterns and related factors.BMC complementary medicine and therapies · 2020Article
- Network Pharmacology-Based Approaches ofBiomolecules · 2020Article
- Outcomes and Toxicology of Herbal Drugs in Alcoholic Hepatitis - A Single Center Experience from India.Journal of clinical and translational hepatology · 2019Article
- Complementary and Alternative Medicine Use in United States Adults With Liver Disease.Journal of clinical gastroenterology · 2017Article
- Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis.Journal of food and drug analysis · 2017Review
- Utilization and prescription patterns of traditional Chinese medicine for patients with hepatitis C in Taiwan: a population-based study.BMC complementary and alternative medicine · 2016Article
- Multiple Chronic Conditions and Use of Complementary and Alternative Medicine Among US Adults: Results From the 2012 National Health Interview Survey.Preventing chronic disease · 2016Article
- Effects of 18α-glycyrrhizin on TGF-β1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis.International journal of clinical and experimental pathology · 2015Article
- Acupuncture in treating hepatic fibrosis: a review with recommendation for future studies.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2012Review
- Coping strategies used by patients infected with hepatitis C virus who are facing medication costs.The Canadian journal of hospital pharmacy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
goalsTo examine a wide range of sociodemographic and clinical characteristics as potential predictors of complementary and alternative medicine (CAM) use among chronic liver disease (CLD) patients, with a focus on CAM therapies with the greatest potential for hepatotoxicity and interactions with conventional treatments.
backgroundThere is some evidence that patients with CLD commonly use CAM to address general and CLD-specific health concerns. STUDY: Patients enrolled in a population-based surveillance study of persons newly diagnosed with CLD between 1999 and 2001 were asked about current use of CAM specifically for CLD. Sociodemographic and clinical information was obtained from interviews and medical records. Predictors of CAM use were examined using univariate and multivariate logistic regression analysis.
resultsOf the 1040 participants, 284 (27.3%) reported current use of at least 1 of 3 CAM therapies of interest. Vitamins or other dietary supplements were the most commonly used therapy, reported by 188 (18.1%) patients. This was followed by herbal medicine (175 patients, 16.8%) and homeopathy (16 patients, 1.5%). Several characteristics were found to be independent correlates of CAM use: higher education and family income, certain CLD etiologies (alcohol, hepatitis C, hepatitis C and alcohol, and hepatitis B), and prior hospitalization for CLD.
conclusionsUse of CAM therapies that have the potential to interact with conventional treatments for CLD was quite common among this population-based sample of patients with CLD. There is a need for patient and practitioner education and communication regarding CAM use in the context of CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.